ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0134

Systemic Lupus Erythematosus Is a Risk Factor for Mortality in Older Patients with Early-Stage Breast Cancer
Abstract Number: 0861

Systemic Lupus Erythematosus, a Pilot Study of a New Disease Activity Score
Abstract Number: 1292

Systemic Lupus Erythematous Readmissions Has Reduced in the Last Decade in the United States: A 9- year Longitudinal Study of the Nationwide Readmission Database
Abstract Number: 0643

Tailored BP Connect Protocol with Implementation Support for Rheumatology Clinic Staff Exceeds Non-tailored Protocol at Improving Primary Care Referrals for Blood Pressure Follow-up
Abstract Number: 1877

Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics
Abstract Number: 1728

Takayasu’s Arteritis and Pregnancy: A Meta-analysis
Abstract Number: 0043

Takinib Inhibits IL-1β-Induced Activation of Signal Transducer and Activator of Transcription 3 (STAT3) in Human Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 0189

Tapering and Discontinuation of Background Therapies During the Transition to Rilonacept Monotherapy in RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Patients with Recurrent Pericarditis
Abstract Number: 0829

Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis: A Systematic Review and Meta-Analyses of Randomised Trials
Abstract Number: 0929

Tapering of TNF Inhibitors in Patients with Axial Spondyloartritis – Can Flare Be Predicted?
Abstract Number: 1804

Targeted Safety Analyses of Guselkumab (TREMFYA®): Long-term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis
Abstract Number: 0544

Targeting CD13/aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis
Abstract Number: 1440

Targeting Endogenous Mesenchymal Stromal Cell Response to Interferong in Sjӧgren’s Syndrome
Abstract Number: 0559

Targeting NNMT as a Novel Metabolic Approach to Treat Systemic Sclerosis
Abstract Number: 0054

TCR Immune Profiling of Patients with Psoriatic Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].